The National Medical Products Administration has approved the marketing of intravenous phosphorolipanitanparonson.

Recently, the National Medical Products Administration approved the application of Fujian Shengdi Pharmaceutical Co., Ltd. for a class 1 innovative drug, injection fosaprepitant palonosetron, which is used to prevent acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adults. The market launch of this drug provides patients with a new treatment option.